



Director/PDMR Shareholding - NMC Health plc

London, 9 September 2015: NMC Health plc (LSE: NMC) ('NMC' or the 'Company'), the leading integrated private healthcare provider operating across the United Arab Emirates and one of the top global providers of fertility treatments through its Spanish subsidiary Clinica Eugin, announces that on 8 September 2015 the following directors of the Company were granted nil cost options over ordinary shares of 10 pence each in the Company under the Company's 2012 Performance Share Plan (the PSP):

Name of individual	Director/PDMR	Number of shares subject to award
Dr B R Shetty	Director	26,298
Mr P Manghat	Director	23,011

The PSP is the Long Term Incentive Plan which the Company operates.

The vesting of the awards granted under the PSP referred to above is subject to the achievement of performance targets relating to the Company's earnings per share growth and total shareholder return (relative to a tailored comparator group of other listed healthcare companies) over a three year performance period.

Contacts

Investors

NMC

Simon Watkins, Group Company
Secretary +44 20 3205 7313

Media:

FTI Consulting, London
Matthew Cole
+44 (0)20 3727 1101

FTI Consulting, Gulf
Shane Dolan
+971 (0)4 437 2100

ABOUT NMC HEALTH

NMC Health plc group is the leading private sector healthcare operator in the United Arab Emirates, with a nation-wide network of hospitals and operations in the country since 1975. The Healthcare Division currently operates or manages eight hospitals, two day-care patient centres, nine medical centres and fifteen pharmacies. In addition, the Group owns and operates Clinica Eugin in Barcelona, Spain - one of the leading fertility treatment centres globally. NMC also owns and operates Americare Group, the leading home care provider in the UAE as well as ProVita, the leading provider of long-term medical care, also in the UAE. The enlarged company received almost 2.8m patients in 2014. The group also operates a significant UAE wide Distribution business supplying product lines across several key market segments, including: Pharmaceutical, FMCG, Food and Scientific and Medical Equipment. NMC Health plc group reported revenues of US\$ 644m in 2014.

In April 2012 NMC Health plc was listed on the Premium Segment of the London Stock Exchange. At the time of its IPO, the group raised funds to enable it to pursue a further growth plan with a number of capital projects for new healthcare facilities in Abu Dhabi and Dubai. NMC Health plc is a constituent of the FTSE 250 Index.